Research and Markets: Global Gene Therapy Market Analysis

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/fff7fa/global_gene_therap) has announced the addition of the "Global Gene Therapy Market Analysis" report to their offering.

Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, future seems to hold significant potential in terms of developing such approaches. Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the long term, as the approach moves from research labs to clinical trials. Gene therapy market is still at the experimental stages with success yet to be achieved in completely developing curative therapeutic drugs.

According to this new research report Global Gene Therapy Market Analysis, the global gene therapy market is anticipated to grow stupendously in the coming years. Presently, large pharmaceutical companies are investing heavily in both, developing such drugs internally and acquiring such candidates from others. The inherent specificity and predictability of gene therapy have shorten the duration of drug development and increased rates of success in preclinical and clinical trials, relative to non-biological small molecule drugs thus, boosting the further growth of the industry.

Key Topics Covered:

  • 1. Analyst View
  • 2. Research Methodology
  • 3. Gene Therapy - An Introduction
  • 4. Industry Trends
  • 5. Industry Overview
  • 6. Research & Development
  • 7. Regulatory Environment
  • 8. Key Players Analysis
  • List of Tables
  • List of Figures

Companies Mentioned:

  • Pfizer
  • GlaxoSmithKline
  • Genentech
  • Astrazeneca
  • Merck KGaA
  • ImClone LLC
  • Ark Therapeutics
  • Celgene Corporation
  • Shenzhen Si Biono Genetech Co. Ltd
  • Takeda Pharmaceuticals

For more information visit http://www.researchandmarkets.com/research/fff7fa/global_gene_therap



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Pharmaceutical  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.